Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombotic Microangiopathies | 9 | 2024 | 65 | 3.700 |
Why?
|
| Complement Pathway, Alternative | 6 | 2019 | 16 | 2.180 |
Why?
|
| Pulmonary Embolism | 4 | 2024 | 342 | 1.580 |
Why?
|
| Thrombosis | 9 | 2024 | 743 | 1.390 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 4 | 2022 | 63 | 1.100 |
Why?
|
| Kidney Glomerulus | 2 | 2018 | 148 | 1.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 7055 | 0.970 |
Why?
|
| Anticoagulants | 5 | 2024 | 777 | 0.840 |
Why?
|
| Endothelial Cells | 4 | 2018 | 1032 | 0.830 |
Why?
|
| Plasma Exchange | 2 | 2024 | 104 | 0.800 |
Why?
|
| Warfarin | 1 | 2023 | 145 | 0.790 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 378 | 0.790 |
Why?
|
| Hemorrhage | 2 | 2023 | 724 | 0.770 |
Why?
|
| Complement Activation | 2 | 2019 | 86 | 0.760 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 364 | 0.700 |
Why?
|
| Complement C3b | 1 | 2019 | 9 | 0.690 |
Why?
|
| Complement Factor B | 1 | 2019 | 11 | 0.690 |
Why?
|
| Patient Care Team | 1 | 2024 | 824 | 0.610 |
Why?
|
| Microvessels | 2 | 2020 | 145 | 0.600 |
Why?
|
| Child | 21 | 2024 | 30572 | 0.550 |
Why?
|
| Protein C | 1 | 2015 | 31 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 589 | 0.490 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 863 | 0.470 |
Why?
|
| Biomarkers | 3 | 2024 | 5050 | 0.430 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 246 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 713 | 0.350 |
Why?
|
| Vena Cava, Inferior | 2 | 2021 | 193 | 0.340 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2022 | 48 | 0.320 |
Why?
|
| Alligators and Crocodiles | 1 | 2008 | 1 | 0.320 |
Why?
|
| Arm Injuries | 1 | 2008 | 15 | 0.320 |
Why?
|
| Amputation, Traumatic | 1 | 2008 | 14 | 0.320 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2021 | 162 | 0.320 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 3 | 2018 | 14 | 0.310 |
Why?
|
| Bites and Stings | 1 | 2008 | 44 | 0.310 |
Why?
|
| Debridement | 1 | 2008 | 126 | 0.300 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 380 | 0.300 |
Why?
|
| Adolescent | 11 | 2024 | 32698 | 0.260 |
Why?
|
| Humans | 32 | 2024 | 270809 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 2024 | 250 | 0.240 |
Why?
|
| Child, Preschool | 7 | 2024 | 17083 | 0.240 |
Why?
|
| Brain | 1 | 2018 | 4199 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2022 | 623 | 0.220 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 48 | 0.220 |
Why?
|
| Infant | 7 | 2024 | 14003 | 0.220 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 191 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2022 | 701 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2024 | 39982 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2022 | 35 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2023 | 115 | 0.200 |
Why?
|
| Thromboembolism | 1 | 2022 | 150 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 1571 | 0.190 |
Why?
|
| Aortic Diseases | 2 | 2024 | 196 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 325 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2024 | 750 | 0.160 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2018 | 14 | 0.150 |
Why?
|
| Complement Factor H | 2 | 2015 | 29 | 0.150 |
Why?
|
| Complement C3a | 1 | 2018 | 21 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2021 | 288 | 0.150 |
Why?
|
| Complement C5a | 1 | 2018 | 32 | 0.150 |
Why?
|
| Receptors, Complement | 1 | 2018 | 46 | 0.150 |
Why?
|
| Immunoassay | 2 | 2015 | 212 | 0.150 |
Why?
|
| Inpatients | 1 | 2022 | 686 | 0.140 |
Why?
|
| Adult | 8 | 2024 | 82074 | 0.140 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 375 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 293 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 2 | 2015 | 768 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 3190 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 758 | 0.120 |
Why?
|
| Hospitalization | 1 | 2024 | 2170 | 0.120 |
Why?
|
| Platelet Activation | 1 | 2015 | 100 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2018 | 486 | 0.120 |
Why?
|
| Male | 11 | 2024 | 128522 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 180 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 532 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 2051 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2015 | 211 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 1117 | 0.110 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 232 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2015 | 702 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2023 | 9464 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 17867 | 0.100 |
Why?
|
| Young Adult | 5 | 2024 | 22255 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6344 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1195 | 0.100 |
Why?
|
| Female | 9 | 2024 | 148940 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2015 | 1420 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6234 | 0.090 |
Why?
|
| Gene Expression | 1 | 2018 | 3606 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5658 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2015 | 3040 | 0.080 |
Why?
|
| Models, Biological | 1 | 2018 | 3187 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8607 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1439 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 2491 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 1113 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2015 | 2440 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1960 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2008 | 293 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 22533 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15280 | 0.060 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 46 | 0.060 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2023 | 66 | 0.060 |
Why?
|
| Thrombectomy | 1 | 2024 | 167 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 71 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 134 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 114 | 0.050 |
Why?
|
| Hemostasis | 1 | 2022 | 98 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1608 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 3155 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 327 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 329 | 0.050 |
Why?
|
| Immunization | 1 | 2022 | 383 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 336 | 0.050 |
Why?
|
| Data Collection | 1 | 2022 | 602 | 0.040 |
Why?
|
| Microcirculation | 1 | 2020 | 189 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 185 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 942 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 4839 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 1102 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 796 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 247 | 0.030 |
Why?
|
| Biopsy | 1 | 2024 | 3490 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2022 | 930 | 0.030 |
Why?
|
| Communication | 1 | 2022 | 841 | 0.030 |
Why?
|
| Weibel-Palade Bodies | 1 | 2015 | 2 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2015 | 79 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 80 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2014 | 8 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 172 | 0.030 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 36 | 0.030 |
Why?
|
| Medical Records | 1 | 2015 | 441 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 2811 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 3287 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2015 | 250 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1218 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 5443 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 61363 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2024 | 33860 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 12979 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4966 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10409 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 9281 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7923 | 0.010 |
Why?
|